FDA Advisory Panel Votes Today on First mRNA Flu Vaccine as MFLUSIVA Phase 3 Results Face Intense Scrutiny
The FDA’s Vaccines and Related Biological Products Advisory Committee met June 18, 2026 to review Moderna’s investigational mRNA seasonal flu vaccine MFLUSIVA (mRNA-1010) for adults 50+; the FDA decision date is Aug. 5, 2026. VRBPAC will vote on traditional approval for ages 50–64 and accelerated approval for 65+. Phase 3 P304 reported RVE of 26.6% vs a standard-dose comparator and 47.9% vs healthcare outcomes, with no major safety issues.
A positive VRBPAC outcome would de-risk FDA approval timing and support the mRNA influenza platform narrative; uncertainties flagged by FDA could cap upside.
FDA VRBPAC convenes June 18 to assess Moderna’s MFLUSIVA mRNA influenza vaccine, with an FDA decision date set for Aug. 5, 2026.
Near-term volatility likely into the vote and Aug. 5 PDUFA; upside skew if panel is favorable, downside risk if FDA concerns dominate.
Background
The FDA’s VRBPAC is holding its first major public evaluation of an mRNA seasonal influenza vaccine since the COVID-19 era, reviewing Moderna’s MFLUSIVA under a bifurcated approval strategy by age group.
Why it matters
The vote is a key de-risking checkpoint for FDA approval timing and label scope (traditional for 50–64; accelerated for 65+), while FDA-identified data gaps could constrain the market’s confidence in durability and breadth of efficacy.
Market relevance
Regulatory milestone (June 18 vote; Aug. 5 decision) plus quantified Phase 3 efficacy and explicit FDA uncertainties create a tradable catalyst window for Moderna’s vaccine program.
Market effects
If approved, could strengthen the read-through for mRNA vaccine platform credibility in seasonal influenza and influence expectations for next-gen respiratory mRNA programs.
Primarily US regulatory-driven; could affect sentiment toward global vaccine developers with mRNA influenza pipelines.
Phase 3 spans North America, Europe, and East Asia, so approval would likely resonate with international influenza vaccine markets and regulators.
Alternative perspectives
Even with no major deficiencies, the FDA’s flagged uncertainties (single-season data and B/Victoria efficacy uncertainty) could lead to a cautious panel stance, limiting approval odds or narrowing the label.
The article emphasizes immunogenicity superiority for 65+ and accelerated-approval framing; traders may underweight the risk that Phase IV confirmatory outcomes could be delayed or fail to validate clinical benefit.
Key entities
- companyModerna
Sponsor of MFLUSIVA (mRNA-1010), an investigational trivalent mRNA seasonal influenza vaccine reviewed by FDA VRBPAC.
- regulatorFDA VRBPAC
Advisory committee convened June 18, 2026 to assess benefit-risk for MFLUSIVA; FDA decision targeted Aug. 5, 2026.
- productMFLUSIVA (mRNA-1010)
Investigational trivalent mRNA seasonal influenza vaccine; Phase 3 Study P304 and immunogenicity comparisons underpin the review.
